West Pharmaceutical Refinanced $203.0 Million Of 2027 Debt Just Before Its Quarterly Report
A new $200 million term loan and $750 million revolver run to 2031, as $685.3 million of buybacks cut cash to $464.1 million.
West Pharmaceutical's 10-Q, filed Thursday, carries $203.0 million of 2027 debt as long-term only because a refinancing closed on October 26, before the statements were issued. The maker of containment and delivery systems for injectable drugs has also spent $685.3 million on buybacks in the first nine months of 2026.
Two 2027 maturities, one new facility
The old debt was a $130.0 million term loan due July 2, 2027, and $73.0 million of 4.02% Series C notes due July 5, 2027. The prior quarter's 10-Q showed the same two maturities alongside a $500.0 million revolver.
The new agreement, with Bank of America as administrative agent, matures October 26, 2031. It pairs a $750 million revolver with a $200 million term loan, which replaced the $130.0 million loan. Quarterly term-loan payments of $1.25 million to $2.5 million start March 31, 2028.
The $73.0 million of Series C notes is slated for repayment on or about November 2, 2026, partly from the new loan. No make-whole premium applies. A leverage covenant caps net leverage at 3.50 to 1.0, rising for big acquisitions. The 8-K says proceeds may fund acquisitions and stock repurchases.
Buybacks drain the cash pile
West bought 2,424,121 shares for $685.3 million over nine months, an average $282.68 a share. Third-quarter buying was $231.0 million, or 663,511 shares, at an average $348.11. A new $1.0 billion authorization approved in February has no expiration date.
Cash fell to $464.1 million at September 30 from $791.3 million at year-end. Operating cash flow for the nine months was $403.4 million, down from $503.7 million a year earlier. Accounts receivable climbed to $748.2 million from $574.4 million, which the company ties to the timing of sales and customer collections.
The stock closed Thursday with a market value of $28.4 billion.
Sales and profit still growing
Third-quarter net sales rose 8.7% to $874.5 million, or 11.9% organically, and diluted earnings per share were $3.02. Proprietary Products, which sells mainly to drug companies, grew 12.6%, led by high-value components. West Vantage, the contract-manufacturing unit, fell 7.3%.
A $55.7 million gain on selling the SmartDose 3.5mL delivery system to AbbVie flattered the quarter's profit, and adjusted EPS was $2.66. The earnings release raised full-year net sales guidance to $3.41 billion to $3.42 billion and adjusted EPS guidance to $9.38 to $9.48.
The Series C repayment is due on or about November 2, 2026, and the new term loan's first payment follows on March 31, 2028.
Sources
- 10-Q Filing — West Pharmaceutical (WST) — SEC EDGAR
- 10-Q Filing — West Pharmaceutical (WST), Q2 FY2026 filed 2026-07-23 (comparison basis) — SEC EDGAR
- 8-K Filing — West Pharmaceutical, filed 2026-10-26 (Items 1.01, 1.02, 2.03, 9.01) — SEC EDGAR
- Earnings release (8-K Item 2.02, exh991q32026earningsrelease.htm) — West Pharmaceutical, filed 2026-10-29 — SEC EDGAR
- West Pharma earnings show why it's more than a GLP-1 play — CNBC
- West Pharmaceutical Earnings: High-Quality Growth and Margin Support Another Guidance Raise — morningstar.com
- Compared to Estimates, West Pharmaceutical (WST) Q3 Earnings: A Look at Key Metrics — Yahoo Finance
- West Pharmaceutical beats top-line and bottom-line estimates; raises FY26 outlook | Seeking Alpha — seekingalpha.com
- WST Q3 Earnings Preview: Will HVP Strength Offset Vantage Weakness? — Yahoo Finance